Sugi Predict

Sugi Predict / Compounds / SCHEMBL1603835

SCHEMBL1603835

SCHEMBL1603835

CCC#CCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ STAT3 P40763 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CA1 P00915 3/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ VDR P11473 1/20 0.38
▸ TLR9 Q9NR96 1/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12611117 0.95 STAT3 (0.38) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL31438232 0.95 STAT3 (0.38) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL7644858 0.93 GAA (0.46) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL7624623 0.87 CA12 (0.40) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL16344942 0.86 GAA (0.41) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL18926551 0.86 CA12 (0.45) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL542839 0.86 GAA (0.43) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL12696531 0.85 STAT3 (0.43) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL4801283 0.84 CYP1A2 (0.44) GAAALDH1A1STAT3CYP3A4CYP2C9
SCHEMBL7579071 0.84 SMN1; SMN2 (0.39) GAAALDH1A1STAT3CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115466162-A Process for preparing (cis ) -3,6, 9-nonadecatriene 虫捕头(苏州)生物科技有限公司 2022-12-13 — — CN claimed
EP-3660014-B1 ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SEOUL NAT UNIV R&DB FOUNDATION (KR) 2023-08-30 — — EP disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 — — US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 — — US disclosed
CN-115466162-A Process for preparing (cis ) -3,6, 9-nonadecatriene 虫捕头(苏州)生物科技有限公司 2022-12-13 — — CN disclosed
CN-109467504-B Process for preparing (4Z,7Z) -4, 7-decadien-1-yl acetate 信越化学工业株式会社 2022-04-08 — — CN disclosed
US-11168081-B2 Alkaloid derivative having angiogenesis inhibitory effect, and pharmaceutical composition containing same SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2021-11-09 — — US disclosed
US-20210087185-A1 ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2021-03-25 — — US disclosed
EP-3453699-B1 PROCESS FOR PREPARING (4Z,7Z)-4,7-DECADIEN-1-YL ACETATE SHINETSU CHEMICAL CO (JP) 2020-06-24 — — EP disclosed
EP-3660014-A1 ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Seoul National University R&DB Foundation (KR) 2020-06-03 — — EP disclosed
US-6469005-B1 CONTROLLING AND PROTECTING AGAINST PHYTOPATHOGENIC MICROORGANISMS SYNGENTA PARTICIPATIONS AG (CH) 2002-10-22 — — US disclosed
EP-1218000-A1 ANTI-CANCER NITRO- AND THIA-FATTY ACIDS WOMEN'S AND CHILDREN'S HOSPITAL (AU) 2002-07-03 — — EP disclosed
EP-1218333-A1 ANTI-INFLAMMATORY NITRO- AND THIA- FATTY ACIDS WOMEN'S AND CHILDREN'S HOSPITAL (AU) 2002-07-03 — — EP disclosed
EP-1140799-A1 NOVEL PROPARGYLETHER DERIVATIVES Syngenta Participations AG (CH) 2001-10-10 — — EP disclosed
EP-1140819-A1 ALFA-SULFENIMINO ACID DERIVATIVES Syngenta Participations AG (CH) 2001-10-10 — — EP disclosed
WO-2001021575-A1 ANTI-INFLAMMATORY NITRO- AND THIA- FATTY ACIDS WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE (AU) 2001-03-29 — — WO disclosed
WO-2001021172-A1 ANTI-CANCER NITRO- AND THIA-FATTY ACIDS WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE (AU) 2001-03-29 — — WO disclosed
WO-2000042007-A1 ALFA-SULFENIMINO ACID DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2000-07-20 — — WO disclosed
WO-2000041998-A1 NOVEL PROPARGYLETHER DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2000-07-20 — — WO disclosed
US-5728376-A Tetradecatrienyl and tetradecadienyl acetates and their use as sex attractants for tomato pests CORNELL RESEARCH FOUNDATION, INC. (US) 1998-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 GAA 452/4885ALDH1A1 1901/4885STAT3 2572/4885
US-11168081-B2 Alkaloid derivative having angiogenesis inhibitory effect, and pharmaceutical composition containing same GPR119, GIPR, UACA GAA 1459/4885ALDH1A1 1012/4885STAT3 359/4885
US-20210087185-A1 ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME GIPR, VEGFA, UACA GAA 1359/4885ALDH1A1 668/4885STAT3 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.